To hear about similar clinical trials, please enter your email below
Trial Title:
Risk Factors and Prediction Model of Cancer-associated Venous Thromboembolism
NCT ID:
NCT05729464
Condition:
Venous Thromboses
Neoplasms
Conditions: Official terms:
Thrombosis
Thromboembolism
Venous Thromboembolism
Venous Thrombosis
Study type:
Observational
Overall status:
Recruiting
Study design:
Time perspective:
Retrospective
Summary:
The purpose of this study is to identify risk factors of cancer-associated venous
thrombosis and develop a prediction model to assist clinicians in tailoring anticoagulant
therapy.
Detailed description:
Venous thromboembolism (VTE) is a prevalent complication in cancer patients. Compared
with the general population, patients with tumors are four to seven times more likely to
develop venous thrombotic events. A population-based cohort study showed that the
incidence of VTE in these patients has increased steadily over the past decade.
Cancer-associated thrombosis may result in discontinuation of antineoplastic therapy,
decreased quality of life, and increased mortality. Clinical trials indicate that
prophylactic anticoagulation leads to a significantly lower rate of thrombotic disorders.
However, due to the fact that thromboprophylaxis treatment increases the risk of bleeding
complications and that the risk of VTE varies widely among individuals, only patients at
high risk of thrombosis will benefit from primary thromboprophylaxis. In this setting,
the use of anticoagulant drugs is challenging. So, the purpose of this study is to
identify risk factors of cancer-associated venous thrombosis and develop a prediction
model to assist clinicians in tailoring anticoagulant therapy.
Criteria for eligibility:
Study pop:
Patients diagnosed with malignant tumors in Tongji Hospital in Wuhan.
Sampling method:
Non-Probability Sample
Criteria:
Inclusion Criteria:
- with a histological diagnosis of cancer.
Exclusion Criteria:
- received long-term anticoagulant therapy;
- without a clear primary site of malignancy;
- had a follow-up of fewer than 6 months.
Gender:
All
Minimum age:
18 Years
Maximum age:
N/A
Healthy volunteers:
No
Locations:
Facility:
Name:
Tongji Hospital
Address:
City:
Wuhan
Country:
China
Status:
Recruiting
Contact:
Last name:
Yongsheng Jiang, doctor
Phone:
02783662356
Email:
ysjiang@163.com
Start date:
December 23, 2022
Completion date:
December 30, 2023
Lead sponsor:
Agency:
Yongsheng Jiang
Agency class:
Other
Source:
Tongji Hospital
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT05729464
